Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer

A phase II study

Gabriella Ferrandina, M. Ludovisi, R. De Vincenzo, V. Salutari, D. Lorusso, M. Colangelo, T. Prantera, M. R. Valerio, G. Scambia

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods: DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results: From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% of cases, respectively. Conclusion: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.

Original languageEnglish
Pages (from-to)1348-1353
Number of pages6
JournalAnnals of Oncology
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

oxaliplatin
docetaxel
Platinum
Ovarian Neoplasms
Therapeutics
Alopecia
Leukopenia
Thrombocytopenia
Anemia

Keywords

  • Docetaxel
  • Ovarian cancer recurrence
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer : A phase II study. / Ferrandina, Gabriella; Ludovisi, M.; De Vincenzo, R.; Salutari, V.; Lorusso, D.; Colangelo, M.; Prantera, T.; Valerio, M. R.; Scambia, G.

In: Annals of Oncology, Vol. 18, No. 8, 08.2007, p. 1348-1353.

Research output: Contribution to journalArticle

Ferrandina, G, Ludovisi, M, De Vincenzo, R, Salutari, V, Lorusso, D, Colangelo, M, Prantera, T, Valerio, MR & Scambia, G 2007, 'Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: A phase II study', Annals of Oncology, vol. 18, no. 8, pp. 1348-1353. https://doi.org/10.1093/annonc/mdm136
Ferrandina, Gabriella ; Ludovisi, M. ; De Vincenzo, R. ; Salutari, V. ; Lorusso, D. ; Colangelo, M. ; Prantera, T. ; Valerio, M. R. ; Scambia, G. / Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer : A phase II study. In: Annals of Oncology. 2007 ; Vol. 18, No. 8. pp. 1348-1353.
@article{af9e41569c884a7b92858767b8a54c06,
title = "Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: A phase II study",
abstract = "Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods: DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results: From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4{\%}. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3-4 leukopenia was documented in 32.5{\%} of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3{\%} and 34.9{\%} of cases, respectively. Conclusion: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.",
keywords = "Docetaxel, Ovarian cancer recurrence, Oxaliplatin",
author = "Gabriella Ferrandina and M. Ludovisi and {De Vincenzo}, R. and V. Salutari and D. Lorusso and M. Colangelo and T. Prantera and Valerio, {M. R.} and G. Scambia",
year = "2007",
month = "8",
doi = "10.1093/annonc/mdm136",
language = "English",
volume = "18",
pages = "1348--1353",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer

T2 - A phase II study

AU - Ferrandina, Gabriella

AU - Ludovisi, M.

AU - De Vincenzo, R.

AU - Salutari, V.

AU - Lorusso, D.

AU - Colangelo, M.

AU - Prantera, T.

AU - Valerio, M. R.

AU - Scambia, G.

PY - 2007/8

Y1 - 2007/8

N2 - Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods: DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results: From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% of cases, respectively. Conclusion: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.

AB - Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months. Patients and methods: DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days. Results: From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% of cases, respectively. Conclusion: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.

KW - Docetaxel

KW - Ovarian cancer recurrence

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=34548150183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548150183&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm136

DO - 10.1093/annonc/mdm136

M3 - Article

VL - 18

SP - 1348

EP - 1353

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -